Pfizer Reports Three-Year ATTR-ACT Data for Vyndaqel in Transthyretin Cardiomyopathy

Pfizer today presented three-year follow-up data from the Phase 3 ATTR-ACT trial evaluating Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) in patients with transthyretin cardiomyopathy (ATTR-CM). The data showed that the mortality and cardiovascular hospitalization benefits of tafamidis were maintained and potentially enhanced over three years of treatment.